Thin
Standardized high-purity API grades (>98.5% by RP-HPLC) manufactured under rigorous stereochemical control, with full structural confirmation by high-resolution MS and complete analytical validation dossiers.
The worldwide shift from glycemic control to total cardiometabolic disease interception has transformed GLP-1 peptide APIs from niche biologics into the world's most volume-demanding therapeutic class.
Global demand for GLP-1 and dual-target incretins (such as semaglutide, tirzepatide, and investigational retatrutide) has repeatedly triggered drug shortages worldwide. Original biopharma brands operating purely on biological recombinant expression systems face biological production bottlenecks, downstream purification limitations, and prolonged batch cycle times.
Consequently, pharmaceutical developers and generic manufacturers are diversifying their supply chains by engaging specialized CDMOs capable of multi-ton chemical synthesis. Chemical solid-phase peptide synthesis (SPPS) offers precise stereocenter maintenance, eliminates biological immunogenic host-cell proteins (HCP), and delivers substantial batch-to-batch reproducibility at competitive unit economics.
While early-generation incretins were primarily expressed via yeast or bacterial recombinant hosts, modern long-acting GLP-1 analogues feature complex non-natural amino acids (e.g., Aib—alpha-aminoisobutyric acid) and fatty diacid side-chain architectures (e.g., C20 diacid attached via mini-PEG or AEEA linkers). These advanced motifs are incompatible with standard ribosomal machinery.
Hangzhou Thinheal Pharma-Tech has invested extensively in resolving the chemical synthesis bottlenecks of long-chain 30+ amino acid peptides. By engineering proprietary orthogonal deprotection chemistry, advanced pseudo-proline dipeptides, and high-efficiency solid supports, we provide reliable, scalable chemical synthesis paths that outperform recombinant yields while delivering purity profiles exceeding USP and EP monographs.
China has established a comprehensive industrial ecosystem for peptide therapeutics, spanning raw amino acids, coupling reagents (HBTU, HATU, DIC/Oxyma), green synthesis solvents, and high-pressure preparative chromatography columns. This integration provides a decisive advantage in securing supply chains against international raw material shocks.
Hangzhou Thinheal Pharma-Tech sits at the center of this industrial cluster in Hangzhou's Heda Medicine Valley. Leveraging multi-ton synthesis facilities, rigorous quality assurance systems aligned with ICH Q7 guidelines, and experienced regulatory documentation teams, Thinheal serves as a trusted global bridge for generic dossiers, clinical trials, and multinational pharmaceutical supply programs.
The clinical landscape is evolving from monovalent GLP-1 receptor agonism toward poly-agonism and non-invasive delivery modalities, imposing unprecedented demands on peptide synthesis purity and yield.
Early-generation peptides such as Exenatide and Liraglutide, culminating in Semaglutide. Defined by direct glycemic stabilization, modest gastric emptying delays, and once-weekly administration achieved through albumin-binding palmitic or stearic diacid side chains.
Unimolecular co-agonists such as Tirzepatide (GLP-1/GIP) and Mazdutide/Survodutide (GLP-1/GCG). Synergistically balancing insulin secretion, hepatic energy expenditure, thermogenesis, and unprecedented 15%–22% systemic weight reduction benchmarks.
Next-generation unimolecular peptides including Retatrutide. Simultaneously triggering three metabolic pathways to accelerate lipid clearance, reverse hepatic steatosis, and achieve weight reductions exceeding 24% in late-phase clinical evaluations.
Engineered cyclic peptides, permeation enhancers (SNAC co-formulations), and non-peptide oral agonists like Orforglipron. Overcoming enzymatic gastrointestinal degradation while retaining high receptor selectivity and oral bioavailability.
| Molecule Name | CAS Registry | Target Receptor Profile | Structural Hallmark / Lipidation | Primary Clinical Indications | Synthesis Complexity Tier |
|---|---|---|---|---|---|
| Semaglutide | 910463-68-2 | GLP-1R Monovalent | Aib8, Lys26 [AEEA-AEEA-γ-Glu-C18 diacid] | T2DM, Obesity, MASH, Renal Insufficiency | High (31 AA) |
| Tirzepatide | 2023788-19-2 | GLP-1R / GIPR Dual Agonist | Dual Aib residues, Lys20 [C20 fatty diacid linker] | Type 2 Diabetes, Severe Obesity, Sleep Apnea | Very High (39 AA) |
| Retatrutide | 2381089-83-2 | GLP-1R / GIPR / GCGR Triple Agonist | Alpha-methyl-functionalized backbone, branched fatty chain | Obesity, T2DM, Hepatic Steatosis (MASH) | Extreme (39 AA) |
| Mazdutide | 2259884-03-0 | GLP-1R / GCGR Dual Agonist | Oxyntomodulin analogue with optimized side-chain fatty acid | Weight Management, Metabolic Syndrome | Very High (29 AA) |
| Survodutide | 2805997-46-8 | GLP-1R / GCGR Co-Agonist | Glucagon-derived backbone with stabilized helix modification | MASH, Fibrosis, Chronic Weight Disorders | Very High (29 AA) |
| Cagrilintide | 1415456-99-3 | Long-Acting Amylin Analogue | Non-selective amylin/calcitonin receptor co-agonist | Combined GLP-1 Therapy (CagriSema) for Obesity | High (37 AA) |
GLP-1 receptor agonists are expanding from diabetes management into widespread multi-organ applications, driving diversified clinical research and customized peptide synthesis programs.
The core clinical indication for GLP-1 analogues remains glucose-dependent insulin secretion paired with glucagon suppression. Peptides synthesized at Thinheal exhibit exact stereochemical conformation, preventing receptor mismatch and providing stable in vivo pharmacokinetics.
Generic formulations and biosimilar projects demand consistent crystalline or lyophilized API forms with defined counter-ion balances (acetate vs. trifluoroacetate) to ensure compatibility with subcutaneous auto-injectors and pre-filled pens.
By crossing or modulating the blood-brain barrier at the arcuate nucleus, GLP-1 peptides stimulate pro-opiomelanocortin (POMC) neurons and inhibit neuropeptide Y (NPY) neurons to decrease hunger signals and prolong gastric transit times.
Our custom synthesis platforms produce dual-target (Mazdutide, Tirzepatide) and triple-target (Retatrutide) analogues at high batch purity, supporting research teams in evaluating sustained lean-to-fat mass preservation ratios.
Metabolic Dysfunction-Associated Steatohepatitis (MASH) represents an urgent unmet global medical need. Dual agonists combining GLP-1 with glucagon receptor (GCGR) agonism activate mitochondrial fatty acid oxidation directly within hepatocytes.
Thinheal synthesizes investigational co-agonists such as Survodutide and Mazdutide under strict quality control standards, ensuring structural integrity for animal efficacy profiling and early clinical safety packages.
Evidence shows GLP-1 receptors in cerebral tissue downregulate neuro-inflammation, restore microglial homeostasis, and clear toxic protein aggregates. Clinical interest in GLP-1 derivatives for neurodegenerative indications has created a demand for high-purity APIs for CNS drug delivery programs.
Thinheal pairs customized synthesis of GLP-1 analogs with CNS-active regulatory peptides such as Selank and Semax, supplying research institutions studying blood-brain-barrier peptide permeability.
Major cardiovascular outcomes trials (CVOTs) have established that long-acting GLP-1 agonists reduce Major Adverse Cardiovascular Events (MACE). Direct endothelial GLP-1 receptor activation improves vascular compliance and stabilizes atherosclerotic plaques.
Thinheal provides pharmaceutical partners with kilogram-scale batches accompanied by stability dossiers, supporting formulation programs focused on heart failure with preserved ejection fraction.
GLP-1 therapy reduces renal inflammation, intraglomerular pressure, and systemic proteinuria in diabetic kidney disease. This has prompted clinical combinations of GLP-1 analogues with SGLT2 inhibitors and non-steroidal mineralocorticoid receptor antagonists.
Thinheal supports clinical researchers with customized peptide libraries, stable isotope-labeled standards, and modified GLP-1/GLP-2 chimeric peptides for precise bioanalytical assays.
Chemical synthesis of 30+ residue lipidated incretins requires disciplined process design to prevent aggregation, control diastereomeric impurities, and achieve commercial scalability.
Peptide aggregation on resin can halt chain elongation through beta-sheet stacking. Thinheal uses low-loading, highly-swelling resins (including specialized 2-chlorotrityl chloride (CTC) and cross-linked PEG polystyrene resins) optimized for long sequences like semaglutide, tirzepatide, and retatrutide.
By modulating resin substitution rates between 0.25 to 0.40 mmol/g, inter-chain interactions are suppressed, maintaining high amino acid coupling efficiency across all 30+ elongation cycles.
Attaching the fatty diacid chain (such as C18 or C20 mono-protected diacids via AEEA-AEEA-γ-Glu spacers) requires precise orthogonal protecting group strategies. We utilize Lys(Mtt) or Lys(Alloc) chemistry to allow site-selective deprotection while preserving main-chain t-butyl, Boc, and Pbf protection.
This orthogonal process minimizes side-chain cross-reactions and prevents racemization at chiral centers, yielding a crude peptide with significantly lower deletion-peptide content.
Global acidolytic cleavage with trifluoroacetic acid (TFA) introduces risks of carbocation alkylation and oxidation of sensitive residues like Trp, Met, and Tyr. Thinheal engineers custom scavenger cocktails (TFA/TIS/EDT/water/phenol) to suppress re-attachment of cleavage byproducts.
Cleavage temperature, duration, and precipitation dynamics in cold methyl tert-butyl ether (MTBE) are automated in multi-ton reactors to preserve peptide integrity.
Crude incretins contain closely-eluting diastereomers, D-amino acid variants, and truncated sequences. Thinheal deploys an industrial two-stage Reverse-Phase HPLC system on high-efficiency C18 and C8 silica columns.
The primary pass uses ion-pairing triethylamine phosphate (TEAP) or ammonium acetate systems to separate related substances, followed by a secondary pass using dilute acetic acid or TFA to eliminate residual salts and yield a bulk solution exceeding 98.5% purity.
Depending on formulation requirements, peptides are converted into acetate, hydrochloride, or sodium salt forms via automated ion-exchange columns. Lyophilization is performed in Class A/Class 100 cleanroom environments.
Optimized freeze-drying cycles regulate freezing velocities, primary sublimation temperatures, and secondary desorption, yielding a fluffy, uniform powder with low residual moisture (<5.0%) and extended shelf-life stability.
Each commercial batch undergoes release testing: RP-HPLC (purity), SEC-HPLC (aggregate distribution), LC-MS/MS (mass accuracy), chiral amino acid analysis (stereochemical integrity), residual solvents by Headspace GC, bacterial endotoxin testing, and bioburden quantification.
Every delivery includes a batch-specific Certificate of Analysis (CoA) and full technical documentation to support global regulatory filings.
Meeting the demands of global generic suppliers, biopharma innovators, and formulation plants requires an integrated infrastructure from clinical discovery to commercial distribution.
Accessing regulated pharmaceutical markets requires defensible CMC documentation. Thinheal prepares comprehensive DMF dossiers aligned with US FDA eCTD Module 3, EMA Common Technical Documents, and NMPA standards.
Our regulatory affairs division provides client audit support, formal validation of analytical methods, process validation data across three consecutive commercial campaigns, and formal stability packages conforming to ICH Q1A(R2) conditions.
Therapeutic peptides are vulnerable to thermal fluctuations and ambient humidity. Thinheal operates temperature-controlled global cold-chain transit pipelines (-20°C standard, -80°C upon request) with integrated GPS and temperature data loggers.
We work with international logistics providers experienced in bio-pharmaceutical customs clearance, ensuring timely delivery to procurement hubs in North America, the European Union, the CIS region, and the Asia-Pacific.
Large-scale solid-phase peptide synthesis consumes significant volumes of polar aprotic solvents such as DMF, NMP, and DCM. Thinheal implements solvent recycling systems that recover and re-purify up to 85% of process solvents via closed-loop fractional distillation.
We are actively adopting greener peptide chemistry protocols, evaluating alternative bio-derived coupling matrices (e.g., 2-MeTHF and Cyrene) to lower E-factors, reduce carbon footprint, and comply with evolving ESG procurement mandates.
Key technical, regulatory, and analytical considerations reviewed by procurement and CMC teams prior to qualification.
Racemization during solid-phase peptide synthesis primarily occurs during activation of protected amino acids, particularly cysteine and histidine, or residues adjacent to sterically hindered amino acids like Aib. We address this using low-epimerization coupling reagents, such as Oxyma Pure combined with DIC, which suppress base-catalyzed enolization.
Furthermore, coupling reactions are run at controlled, moderate temperatures without excess tertiary amine bases. Every commercial lot undergoes chiral amino acid analysis (GC-MS or chiral derivatization HPLC) after total acid hydrolysis, validating that D-amino acid enantiomers remain below strict pharmacopeial thresholds (typically <0.5%).
We deploy an orthogonal side-chain protection strategy. During automated chain elongation on resin, the specific lysine residue destined for acylation (Lys26 in Semaglutide, Lys20 in Tirzepatide) is introduced with an acid-labile protective group such as 4-methyltrityl (Mtt) or an enzymatically/Pd-cleavable Alloc group.
After selective cleavage of this orthogonal group without perturbing other protecting groups, the side-chain is built step-by-step or coupled as a pre-synthesized fragment (e.g., Mono-tBu-octadecanedioic acid-γ-Glu(OtBu)-AEEA-AEEA-OH). This approach eliminates side-chain misdirection, avoids undesired acylation at the peptide N-terminus, and maintains high crude purity prior to global cleavage.
Long incretin chains frequently exhibit sequence-dependent self-aggregation due to intermolecular hydrogen bonding along the peptide backbone. Thinheal prevents this by strategically introducing pseudo-proline dipeptides (oxazolidine or thiazolidine derivatives of Ser, Thr, or Cys) and Dmb/Hmb backbone protecting groups at known aggregation-prone regions.
These elements disrupt beta-sheet conformation by introducing steric kinks. Additionally, we utilize swelling solvents like NMP/DMF blends with microwave-assisted or temperature-regulated agitation, ensuring complete amine acylation across difficult sequence stretches.
Yes. While research-grade peptides are frequently isolated as TFA salts due to the standard TFA/water/acetonitrile mobile phases used in reverse-phase HPLC, therapeutic-grade peptides intended for in vivo animal studies or clinical development generally require acetate or sodium forms to eliminate residual TFA toxicity.
Thinheal operates automated preparative ion-exchange chromatography systems. We exchange TFA for acetate, verifying complete conversion by ion-chromatography (IC) or 19F-NMR testing to ensure residual fluoride/TFA remains well below typical regulatory specifications (often <0.1% or undetectable).
Every commercial and clinical batch of GLP-1 peptide API is shipped with an extensive, batch-specific Certificate of Analysis (CoA). This includes analytical data from RP-HPLC (chromatographic purity and related substances profiles), high-resolution electrospray ionization mass spectrometry (HR-ESI-MS), peptide content analysis (elemental or amino acid analysis), and moisture content (Karl Fischer titration).
Upon request under technical agreement, Thinheal provides comprehensive regulatory documentation including 1D/2D NMR spectrum verification, circular dichroism (CD) secondary structure analysis, residual solvent profiles (Headspace GC), bacterial endotoxin verification (<10 EU/mg standard, lower specifications available), and stability summaries aligned with ICH guidelines.
Hangzhou Thinheal operates an integrated R&D facility and dedicated commercial production base with cumulative chemically synthesized peptide capacity reaching multi-ton scales. Our manufacturing infrastructure includes solid-phase reactors up to 1,000 liters, coupled with preparative HPLC columns ranging from 150mm to 600mm internal diameters and industrial cleanroom freeze dryers.
For custom CDMO campaigns, pilot scale-up (grams to kilograms) typically requires 4 to 8 weeks depending on sequence complexity, while multi-kilogram commercial production schedules are structured to maintain consistent, long-term supply continuity for international formulation partners.
Therapeutic-grade commercial batches, neuroprotective agents, dual incretin agonists, and custom peptide analogues manufactured under validated process conditions.
Connect directly with our dedicated regional commercial managers for rapid responses, custom project quotes, and technical dossier access across your market's time zone.
Commercial regulatory supply, US FDA filing assistance, and European monograph alignment.
[email protected] WhatsApp: +86 188 5815 8962Eurasian customs integration, bilingual technical documentation, and bulk supply coordination.
[email protected] WhatsApp: +86 199 5636 9799Fast logistics channels across East Asia, South Asia, and regional CRO/clinical partnerships.
[email protected] WhatsApp: +86 136 2847 6528Bespoke commercial batch production, generic formulation support, and cold-chain air freight.
[email protected] WhatsApp: +86 133 5715 0101